- Home
- INSM vs SOFI Comparison
INSM vs SOFI Comparison
Compare INSM & SOFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INSM | SOFI |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 33.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INSM | SOFI |
|---|---|---|
| Price | $156.33 | $25.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 22 | 15 |
| Target Price | ★ $187.55 | $25.75 |
| AVG Volume (30 Days) | 2.5M | ★ 44.4M |
| Earning Date | 02-19-2026 | 01-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 357.55 |
| EPS | N/A | ★ 0.54 |
| Revenue | $447,022,000.00 | ★ $3,290,639,000.00 |
| Revenue This Year | $49.51 | $37.15 |
| Revenue Next Year | $134.47 | $27.23 |
| P/E Ratio | ★ N/A | $48.13 |
| Revenue Growth | 30.34 | ★ 30.62 |
| 52 Week Low | $60.40 | $8.60 |
| 52 Week High | $212.75 | $32.73 |
Technical Indicators
Market Signals| Indicator | INSM | SOFI |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 43.14 |
| Support Level | $153.19 | $24.95 |
| Resistance Level | $164.62 | $26.39 |
| Average True Range (ATR) | 7.67 | 1.22 |
| MACD | -0.76 | -0.12 |
| Stochastic Oscillator | 9.60 | 16.31 |
Price Performance
Historical ComparisonAbout INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.